Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 19/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12176203 | 0.88 | NPSR1 (0.44) | CYP2C9 | |
| SCHEMBL14960484 | 0.87 | UBE2M (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL18790110 | 0.87 | UBE2M (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL13326991 | 0.87 | UBE2M (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL12176516 | 0.86 | CFD (0.46) | CFDKLK7ADORA3CYP2C9PTGS1 | |
| SCHEMBL14959021 | 0.85 | ALDH1A1 (0.56) | CYP2C9 | |
| SCHEMBL18609476 | 0.85 | ALDH1A1 (0.45) | CYP2C9 | |
| SCHEMBL14959038 | 0.85 | ALDH1A1 (0.45) | CYP2C9 | |
| SCHEMBL12176191 | 0.84 | ALDH1A1 (0.43) | CYP2C9 | |
| SCHEMBL18532606 | 0.84 | ALDH1A1 (0.43) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102258-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20170114017-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9573897-B2 | C5AR antagonists | CHEMOCENTRYX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160229802-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-08-11 | — | — | US | disclosed |
| US-9126939-B2 | C5AR antagonists | CHEMOCENTRYX, INC. | 2015-09-08 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20110275639-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275639-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CFD 24/4885KLK7 2693/4885ADORA3 121/4885 |
| US-20170114017-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CFD 24/4885KLK7 2693/4885ADORA3 121/4885 |
| US-20160229802-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CFD 24/4885KLK7 2693/4885ADORA3 121/4885 |
| US-20230102258-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CFD 24/4885KLK7 2693/4885ADORA3 121/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | CFD 24/4885KLK7 2693/4885ADORA3 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.